Literature DB >> 15863809

Substance abuse in first-episode bipolar I disorder: indications for early intervention.

Christopher Baethge1, Ross J Baldessarini, Hari-Mandir Kaur Khalsa, John Hennen, Paola Salvatore, Mauricio Tohen.   

Abstract

OBJECTIVE: This study clarified the early characteristics of substance use disorders in patients with first-episode bipolar I disorder.
METHOD: The authors evaluated substance use disorders, associated factors, and clinical course, prospectively, in the first 2 years of DSM-IV bipolar I disorder with standardized methods.
RESULTS: Baseline substance use disorder was found in 33% (37 of 112) of the patients at baseline and in 39% at 24 months. Anxiety disorders were more frequent in the patients with than without substance use disorder (30% and 13%, respectively). Associations of alcohol dependence with depressive symptoms and cannabis dependence with manic symptoms were suggested. Patients using two or more substances had worse outcomes.
CONCLUSIONS: Since substance use disorders were frequent from the beginning of bipolar I disorder and were associated with anxiety disorders and poor outcome, early interventions for substance use disorder and anxiety might improve later outcome.

Entities:  

Mesh:

Year:  2005        PMID: 15863809     DOI: 10.1176/appi.ajp.162.5.1008

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  20 in total

Review 1.  Cannabinoid-related agents in the treatment of anxiety disorders: current knowledge and future perspectives.

Authors:  Simone Tambaro; Marco Bortolato
Journal:  Recent Pat CNS Drug Discov       Date:  2012-04-01

2.  Misdiagnosis of bipolar disorder.

Authors:  Tanvir Singh; Muhammad Rajput
Journal:  Psychiatry (Edgmont)       Date:  2006-10

3.  Risk and protective factors associated with substance use disorders in adolescents with first-episode mania.

Authors:  Jacob R Stephens; Jaimee L Heffner; Caleb M Adler; Thomas J Blom; Robert M Anthenelli; David E Fleck; Jeffrey A Welge; Stephen M Strakowski; Melissa P DelBello
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2014-05-10       Impact factor: 8.829

4.  Cannabis involvement in individuals with bipolar disorder.

Authors:  Arpana Agrawal; John I Nurnberger; Michael T Lynskey
Journal:  Psychiatry Res       Date:  2010-07-31       Impact factor: 3.222

5.  Treatment guidelines for substance use disorders and serious mental illnesses: do they address co-occurring disorders?

Authors:  Brian E Perron; Alicia Bunger; Kimberly Bender; Michael G Vaughn; Matthew O Howard
Journal:  Subst Use Misuse       Date:  2010-06       Impact factor: 2.164

6.  Expression of CB1 cannabinoid receptor in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression.

Authors:  D Koethe; I C Llenos; J R Dulay; C Hoyer; E F Torrey; F M Leweke; S Weis
Journal:  J Neural Transm (Vienna)       Date:  2007-03-19       Impact factor: 3.575

7.  Improving treatment adherence in bipolar disorder: a review of current psychosocial treatment efficacy and recommendations for future treatment development.

Authors:  Brandon A Gaudiano; Lauren M Weinstock; Ivan W Miller
Journal:  Behav Modif       Date:  2008-05

8.  Depression precipitated by alcohol use in patients with co-occurring bipolar and substance use disorders.

Authors:  William B Jaffee; Margaret L Griffin; Robert Gallop; Christina S Meade; Fiona Graff; Rachel E Bender; Roger D Weiss
Journal:  J Clin Psychiatry       Date:  2008-12-30       Impact factor: 4.384

Review 9.  Clinical and legal characteristics of inmates with bipolar disorder.

Authors:  Cameron D Quanbeck; Barbara E McDermott; Mark A Frye
Journal:  Curr Psychiatry Rep       Date:  2005-12       Impact factor: 8.081

10.  Clinical presentations of substance abuse in bipolar heroin addicts at time of treatment entry.

Authors:  Icro Maremmani; Angelo Giovanni Icro Maremmani; Fabio Rugani; Luca Rovai; Matteo Pacini; Silvia Bacciardi; Joseph Deltito; Liliana Dell'osso; Hagop S Akiskal
Journal:  Ann Gen Psychiatry       Date:  2012-09-03       Impact factor: 3.455

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.